Atea Pharmaceuticals, Inc.

Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals Third Quarter 2023 Financial Results and Business Update conference call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call up for your questions. I would now like to turn the call over to Janae Barnes, Senior Vice President of Investor Relations and Corporate Communications at Atea Pharmaceuticals. Ms. Barnes, please proceed.

Thank you, operator. Good afternoon, everyone, and welcome to Atea Pharmaceutical's third quarter 2023 financial results and business update conference call. Earlier today, we issued a press release which outlines the topics we plan to discuss. You can access the press release as well as the slides that we'll be reviewing today by going to the investor section of our website at ir.ateapharma.com. With me today from Atea are our chief executive officer and founder, Dr. John Pierce-Amadosi, Chief Development Officer, Dr. Janet Hammond, Dr. Arantahorga, Chief Medical Officer, Andrea Corcoran, Chief Financial Officer and Executive Vice President of Legal, and our Chief Commercial Officer, John D'Avrica. They will all be available for the Q&A portion of today's call. Before we begin the call, and as outlined on slide two, I would like to remind you that today's discussion will contain forward-looking statements that involve risk and uncertainties. These risks and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission, which we encourage you to read. Our actual results may differ materially from what is discussed on today's call. With that, I'll now turn the call over to Jean-Pierre.

Thank you, Janaye. Good afternoon, everyone, and thank you for joining us. Since the beginning of the year, we made great progress across our COVID-19 and HCV programs. So as you can see on slide three, for our COVID-19 program, enrollment in Sunrise, our global phase three, reflect the inflection rates occurring globally and the study global footprint. Supported by clinical data, including favorable efficacy, safety, and lack of drug interaction profile of Benipozivir, we are pleased with the progression of Sunrise 3 study and we look forward to several important milestones in 2024. Our goal for this program is to deliver an effective treatment to the millions of patients for whom the current standard of care is not adequate. COVID is here to stay, and the area where there is great vulnerability is the urgent need for additional oral antivirals. We believe that venifosfevir has the potential to address the key limitations of current COVID-19 therapies, including safety and drug-drug interactions. New, safe, and well-tolerated oral therapies are also needed to keep up with the evolution of the virus. The SARS-CoV-2 virus indeed is accumulating mutations with amino acid substitutions faster than any other endemic RNA route. To prevent the emergence of cross resistance, we need a broader and more diversified arsenal of all anti-routes with various distinct mechanism of action. As part of a multi-pronged approach against COVID-19, we continue to also make progress with our discovery program focused on the second generation protease inhibitor that is highly differentiated and has a well-suited clinical profile, and we expect to share an update sometime early next year. For our HCV program, we are very pleased with the substantial progress made in our Phase II combination study of benifosbuvir and rosasvir. We have quickly completed enrollment of the 60 patient leading cohorts, and initial results are expected in early 2024. Our goal for this program is to substantially enhance the current standard of care by offering an eight-week, pan-genotypic, protease-free treatment option for HCV patients. Despite treatment options, indeed, they remain a large, underserved HCV patient population that continues to grow dramatically even in the United States due to the opioid crisis, injection drug use, and HCV reinfection. For both our COVID-19 and HCV program, which are each multi-billion dollar commercial opportunities, we are well capitalized to achieve key inflection points with a cash runway well into 2026. Of September 30th, we add $595.1 million of cash and cash equivalents, and Andrea will go over the details with you. I will now turn the call over to Janet for an update on our COVID-19 program.

Good afternoon, everyone. As Jean-Pierre just stated, COVID-19 variants are continuing to evolve at a very rapid pace. On slide five, you can see how As quickly as every two weeks, the variant proportions in the United States are changing based on genomic sequencing results. These rates are faster than reported for any other RNA virus. And you can see why it isn't surprising that there are so many new variants circulating, and it isn't possible to predict how these variants might further evolve in terms of which mutations come next and the associated rates of infectivity and ability to cause severe disease. The CDC is currently monitoring 35 variants, of which HV1 is the latest to be the dominant strain. But there are hundreds more that haven't yet reached the level of community spread to appear on their radar. Not showing up on this slide yet is the variant of Omicron BA286, and it's a new mutation, which is called JN1, which contains a further 41 additional unique mutations compared to HVB1.5. As you can see, as a result of this, we're caught in a perpetual game of catch-up with continual attempts at updated vaccines that are often outdated before they become available. Each new variant introduces mutations that can impact vaccine efficacy and durability. On top of this, first-generation monoclonal antibodies have quickly become obsolete with authorizations revoked due to waning efficacy. Alarmingly, it is apparent that some recently circulating variants seem to have resulted from the use of monoclonal antibodies. All of this underscores the important role for direct-acting oral antivirals, which are effective independent of new mutations. Importantly, demifosavir has a high barrier to resistance due to its unique mechanism of action, maintaining potency against all variants tested to date. And we anticipate that this will be the case as new variants continue to emerge. Turning to slide six. Supported by our extensive global footprint, we're seeing promising enrollment trends in our Sunrise 3 trial. We have strong patient enrollment in the US, where clinical sites have been responsible for approximately 50% of the patients to date. The majority of patients globally continue to be enrolled in the monotherapy arm, despite the awareness and availability of current oral antiviral options. This clearly highlights the ongoing important unmet medical need which continues due to safety concerns, tolerability, and potential drug-drug interactions which limit the use of the currently available agents. Heading into this winter, forecasts from the US CDC suggest that this respiratory season should be similarly high to last year. where hospitals were more full than at any other time point in the pandemic and worse than pre-pandemic years. It's predicted that COVID-19 will likely account for approximately half of those hospitalizations, with flu and RSV combined accounting for the other half. There's a very low COVID-19 booster uptake, with the latest vaccine at approximately only 7% of U.S. adults. which leaves many susceptible to the virus without a suitable treatment option. The most vulnerable to severe COVID infection are the elderly, the immunocompromised, and those with underlying risk factors for severe infection. Turning to slide seven, as a reminder, Sunrise 3 is focusing on high-risk patients, and its primary endpoint is all-cause hospitalization or death through day 29, in approximately 2,200 patients in the supportive care monotherapy arm. There are two planned interim analyses for DSMB review at approximately 650 patients and again at 1,350 patients in the supportive care monotherapy arm, with initial top-down data also anticipated next year. These notes, the DSMB's review, we do not expect to report efficacy results. These analyses are primarily geared towards safety and futility. In April, we were granted fast-track designation for benifostavir, which reflects the recognized unmet medical need that remains for COVID-19 patients. We believe that the compelling profile of benifostavir has differentiated both clinically and preclinically, with its low risk for drug interactions and its good tolerability profiles, as well as the absence of mutagenicity and embryo-fetal toxicity in the preclinical studies. Our goal for COVID-19 is to deliver a safe, tolerable, and effective treatment to the millions of patients for whom the current standard of care is not a suitable option. I'm now going to hand the call over to John to review the COVID-19 commercial opportunity.

Good afternoon, everyone. On slide nine, Let's discuss the COVID-19 landscape of active oral antiviral programs in clinical development in the U.S. under FDA review. As you can see, Sunrise 3 is the only phase 3 program in the U.S. that is evaluating a new oral antiviral exclusively for the treatment of high-risk patients. Turning to slide 10, the prescription demand for oral antivirals to treat COVID-19 correlates with the infection rates. The demand for oral antivirals in 2023 has been considerable and shows that the US is averaging approximately 580,000 scripts per month, January through September. Turning to slide 11, as of November 1st, the market for COVID-19 oral antivirals began transitioning to the traditional payer markets, such as Medicare, Medicaid, and private commercial insurance. Oral antiviral therapeutics for COVID-19 are expected to remain a multi-billion dollar opportunity for years to come. Projected annual COVID-19 oral antiviral U.S. demand using IQVIA retail prescriptions suggests an estimated annual global market opportunity of approximately $10 billion. And to our knowledge, this has become one of the the largest antiviral markets, concentrated with only two products that have key limitations. We believe there is still an unmet need with critical gaps, and there is an opportunity to expand this market to patients where Paxlovid tolerability and drug-drug interactions is a concern, in addition to the safety concerns with Ligabrio. I'll now turn the call over to Arantxa to review our Phase II HCV program.

Thank you, John. Moving now to slide 13, let's discuss our Phase II hepatitis C program, a novel combination of benifosfovir and rusosvir. We recently achieved an important milestone, and we completed enrollment of the 60-patient leading cohort. In this cohort, we are evaluating the combination of benifosfovir and rusosvir for safety, tolerability, and sustained biological response, or SVR, at week four. The primary endpoint of the study remains at SVR week 12. But as you may know, there is an accepted correlation between SVR at weeks 4 and 12. And utilizing this correlation allows us to accelerate the study. Patients will complete treatment this quarter. And factoring in the timeline for data analysis, we expect to announce initial results early 2024. We are expanding the study geographical footprint to approximately 50 clinical sites in 15 countries, and we plan to reinitiate enrollment after we review the results from the leading cohort. We are receiving global regulatory approvals for the remainder of the trial, and our broad investigation network will help to lay the groundwork for the anticipated initiation of a global phase three trial, which is expected in the fourth quarter of 2024. Slide 14 outlines our Phase II open-label study of benifosforbid and russosvir in hepatitis C patients. This study is expected to involve a total of approximately 280 antiviral knife patients across all genotypes, including the leading cohort of 16 patients. Patients administer 550 milligrams of benifosforbid in combination with 180 of russosvir once daily for eight weeks. The primary endpoints of the study are safety and sustained biological response, or SVR with 12, post-treatment. Other biological endpoints include biological failure and viral resistance. We believe that the combination of benifosfovir and rusosvir has the potential to substantially improve upon the current standard of care by offering a protease inhibitor-free, eight-week duration option for hepatitis C patients with and without cirrhosis. I would like to note, before I hand over the call to Andrea, that we will be presenting two posters at the 2023 Annual Meeting of the American Association for the Study of Liver Diseases later this week. They include supportive data for benifosfavir and rusosvir, highlighting the potential to use these two drug candidates together as a novel treatment for hepatitis C. And with that, I will now turn the call over to Andrea to summarize Atea's financial position.

Thank you, Arentha. As Jonay mentioned in her introductory remarks, earlier today we issued a press release containing our financial results for the third quarter of 2023. The statement of operations and balance sheet are on slides 16 and 17. For the third quarter 2023, G&A expenses remain relatively consistent with the third quarter of 2022. There was an increase in R&D year-over-year third quarter related to the advancement of our COVID-19 and HCV clinical programs. We do anticipate that R&D expenses will continue to increase in a measured way as these programs continue to advance. We are exercising focused financial discipline to manage spend as we invest in both of these programs. At the end of the third quarter of 2023, our cash, cash equivalent, and marketable securities balance was $595.1 million. Based on our current plans, we are reiterating our cash guidance with a runway well into 2026. I'll now turn the call back over to Jean-Pierre for closing remarks.

So in closing, we have made great clinical and operational progress across our COVID-19 and HCV programs so far this year. We have also published and presented significant scientific and clinical evidence in support of the potential of our clinical programs among an audience of leading virologists and infectious disease specialists at several scientific conferences this year. We will continue to highlight the potential of our programs at upcoming scientific conferences, including ASLD later this week, and through the publication of our data. We know the clinical data are very important, and the number of interim analysis and data readouts starting in early 2024, we believe that next year will be transformational for ATHER. As always, We thank you for your continued interest and support of ATERAS. Together, we strive to address the unmet medical needs of patients with serious bowel diseases. With that, operator, we will now open the call up to your questions. Thank you, sir.

In order to ask a question, please press TAR11 on your telephone and wait for your name to be announced. to withdraw your question, please press star 11 again. Please stand by while we compile the Q&A roster. Our first question comes from the line of Eric Joseph with JP Morgan. Your line is now open.

Good evening. Thanks for taking the questions. I guess just having pushed out the timeline for the first interim analysis here a little bit for Sunrise 3, can you talk about the pace of enrollment in the study and ultimately your level of confidence in being able to fully enroll the trial should the interim analyses support. And I guess with respect to the interim analysis itself, other than for fertility, ruling that out, how does the interim sort of de-risk the study from an efficacy perspective? Can you speak to that a little bit?

So, Eric, related to the timelines, I'd like to remind you that on our last earning call for Sunrise 3, we said our first interim analysis will be around year end 23 or Q1 24. And we are just planning for Q1 24. So, I don't think that we change any timeline, and we are on track with this timeline. Related to the detail for the interim analysis what the DSMB will do and our projection. Janet, can you address the rest of the question, please?

Sure. So, first of all, thanks for the question, Derek. With regard to the pace of enrollment, I think the pace of enrollment is very commensurate with what one is seeing worldwide in terms of surges. There was, I think, a perception and I think a great hope by everybody, really, that towards the beginning of summer that COVID might actually at last be going away. But then I think we all experienced the fact that there was a huge surge at the end of July into August and early September. I think this is somewhat subsided now, but we are starting to hear reports of the next surge really starting up in Europe. And we anticipate that there will be a considerable surge as we head into the holiday season, unfortunately. So we have a very broad geographical footprint for this trial. And so we have, as was mentioned, I think, previously, we have the anticipation of having in excess of 300 sites across the world available to enroll patients as these surges occur. And so we're pretty confident that we can, assuming all else goes well, as you mentioned, with regard to the DSMBs, enroll the trial. And unfortunately, it does seem that one surge is going to follow another. I think with regard to what the DSMB can answer for us in regard to things other than futility, I think it's primarily going to be around the safety profile being acceptable for us to continue to enroll patients. and that we're not doing anybody any harm by continuing to keep the trial open from that perspective. But with regard to efficacy, no, we won't have any readout from them in that regard, just that it's safe to proceed.

Okay, that's helpful. I guess, could you similarly frame the second interim as well in terms of, you know, what... what that might inform from an efficacy's perspective, if not the first interim.

So I think both interim analyses are really designed primarily towards ensuring that the study is able to achieve its primary endpoint of hospitalization and that these hospitalizations are being distributed in a way where we should be able to continue the trial and achieve a readout at the end. But beyond that, we will not have any efficacy information. So they will just allow us to proceed assuming it's not too sound.

Okay, great. Thanks for taking the questions.

One moment for the next question. Your next question comes from the line of Maxwell-Hakor with Morgan Stanley.

Your line is now open.

Great. Thank you. So I'm trying to put Sunrise 3 into context, given lower hospitalization rates in the competitive landscapes. Specifically, Gilead announced that their oral phase 3 trial is fully enrolled with approximately 1,900 participants at standard risk. I think their data is expected in early 24. So have you thought about revisiting standard risk patients with a primary endpoint other than viral load to accelerate development? Thank you.

Janet, do you want to address the question? And thank you, Matt, for the question.

Yeah? So, yes, thank you for the question. And, yes, of course we have considered that. But we actually do believe that hospitalization is probably the most important benefit that can be achieved from using a direct oral antiviral. And I think there are some important differences between our trial and that. And you'll recall that Gilead had two trials ongoing. They had one which they terminated in higher risk patients, and then they have a standard risk patient population where they're looking for a reduction in symptoms. And our study is a bit more like the one which they terminated, but the study which they terminated, unlike ours, was not enrolling in the U.S. And as I mentioned in my remarks, what is striking to us is that about 50% of the patients that we are enrolling in our trial are coming from the U.S. And I think And that's partly due to the fact that I think throughout there have been substantial, perhaps more substantial education and availability of testing for patients. And I think an awareness of COVID in high risk, vulnerable patient populations in the US. And so we continue to believe that our study should be able to be enrolled in this patient population, perhaps because of some of this differentiation that we have. We are obviously continuing to watch and understand what others are able to observe, and we'll continue to evaluate and assess what adjustments are needed to be made. But at the moment, we believe that this is the patient population where the need is the greatest, and also that because of our geographical footprint, it is something that we should be able to achieve.

Okay. Thank you. One moment for the next question. And your next question comes from the line of John Miller with Evercore.

Your line is now open.

Hi, guys. Thanks for taking my question. I guess given that we're not going to get efficacy in the interim looks, Do you have any sense at this point when you anticipate having a good sense for efficacy when that could be communicated to us out of Sunrise 3? I'm aware it's based on event rate, but do you have any sense based on your expectations for curves and for surges when that could happen?

Janet? Thank you, John, for the question. Janet?

I think probably the answer is unfortunately no. I think that's the difficulty with COVID is that, you know, I think the surges are somewhat unpredictable and the study needs to remain blinded in order for us to be able to take it across the finishing line.

Fair enough. Maybe transitioning to that novel PI that we'll get an update for in the first quarter, do you expect to have a candidate at that time? Will there be preclinical data for us to talk about? I'm just trying to get a sense for what you might be communicating in that update.

Well, John, it will be preclinical data. And to be honest with you, as the profile will be very different from any PI that has been identified approved or is in clinical development. We like to keep a little bit more time before we will release this information because there is a lot of competitive intelligence that we are concerned that that will open a field that we believe we are going to be pioneer there. So it's not going to be the standard, either peptidomebenic or small molecule, once or twice a day, and mostly all cross-resistant to Paxlovid. So it's really a new generation and also with a very different target profile that we are working on. For competitive reasons, we prefer to hold for now and share with you when we feel that we have a little bit more security field and make a little bit later, I would say, more progress and more into the preclinical development.

All right. Thank you very much.

One moment for the next question. And your next question comes from the line for Ronna Ruiz with Lyrinc Partners.

Your line is now open.

Thanks, operator. This is Rosa Chun on for Ronna Ruiz at Lyrinc Partners. Just a quick one on COVID and then a follow-up on your HCV program. So do you have a sense for how much your recent trial amendments for Sunrise 3 has maybe impacted your enrollment where you expanded your patient eligibility requirements?

Janet, do you want to address the question?

So the amendment is achieving regulatory approvals, and we are seeing in the places where the regulatory approvals have been achieved that we are certainly enrolling patients with a slightly broader profile than initially, but I think we have yet to see the full benefit of it, as it takes a little while in some cases for the approvals to come all the way through. I think we've certainly benefited from the surge we can see, and also I think from the fact that we have as many sites open as we do, and so we're well positioned, I think, to take advantage of these surges now as they come through, and we're seeing enrollment and moving forward quite well. Thank you.

Thanks so much. And regarding HCV, can you remind us who are the early adopters that you're hoping to target in the market? And separately, do you see your combination as differentiated enough from what's currently available to be able to possibly take larger market share in the future if launched?

John, you want to address the question?

Yeah, so thank you for the question. As you know, the global net sales market for Hep C is quite large, and in 2022, I think the net sales is approximately $3.5 trillion, so with the U.S. representing roughly 50% of that. So there's definitely room for more than just two players, but for, you know, our profile that we believe we should be and hopefully be able to achieve, you know, it's going to be pan-geotypic, protease-free, protein inhibitor-free, and also to have no food effect. And, you know, being an AV therapy, it should be able to compete quite well within that market for share. And obviously, how much share will depend on the final clinical profile that is demonstrated. But we feel very confident that a market of that size can easily accommodate three products.

That's helpful. And if I could, with a follow-up, do you have a sense for what the FDA is looking for in your Phase III trial design? Because previously you mentioned the combo has the potential to be less than eight weeks of treatment, which would be quite a differentiating factor. Is that something you'll build into the Phase III trial design to be able to see that?

Well, look, first, we never say that we are going to go to a lesser. We say that we have the potential. possibly, so we don't have even the data right now. So let's await the data. We feel, as John has indicated, I share with you, that there is not, I would say, bluntly an for eight weeks, which is considered today the standard of care, when we know it's a very different market, as John also indicated, as compared to 10 years ago, where the patients were garaged. their new patients. Compliance is a major, actually, it's a major issue. Mostly IV drug abusers, opioid, the opioid crisis, reinfection. Shorter time is highly differentiated, especially eight weeks. We'll see if we, later on, in parallel to the phase three, we will go to the to a potential six weeks, but definitely we anticipate that for phase three, we will go eight weeks, as we said, as a head-to-head against Ipclusa, which we believe, consider, and agree by all the pathologists and ID specialists being the standard of care. At this time, I don't think that we can share with you any of the interaction beyond the Phase II with the regulators and when we do, we will share with you. But right now, it's too early. Let's see the data on the Phase II and then after, as we mentioned, we'll go head-to-head in one of the Phase V against ACRUSA and then let us discuss with the regulators about how they see this study design, phase three study design.

Appreciate the color. Thanks so much.

And your last question will come from Tim Lugo with William Blair. Your line is now open.

Hi, team. This is John on for Tim. Thanks so much for taking our questions. I was just wondering if you could remind us on what you'll announce for the interim DSMB analysis in the first quarter. Will you just announce that the DSMB either recommended continuing or stopping the study, or will you provide some initial safety data as well?

Janet, you're going to address the question.

I think we'll just really announce that we can continue or not. Yeah.

Okay. That's very helpful. Thanks.

And we have no further questions at this time. I will now turn the call back over to Jean-Pierre Samajosi.

Thank you again for joining us today. This is the end of our call. Thank you.

This concludes today's conference call. Thank you for your participation. You may now disconnect.